The solution to non invasive diagnosis of functional gastrointestinal disorders
G-Tech Medical News
G-Tech is excited to announce a significant milestone, the GutCheck patch has now been used on the 50th in-hospital patient to study their postoperative recovery following an abdominal surgery. 11/10/16
G-Tech's Anand Navalgund, Phd is a recipient of the Young investigator award for his scientific accomplishment in the American Gastroenterological Association’s competition at the 2016 Digestive Disease Week® (DDW) meeting in San Diego, CA. 5/21/16
G-Tech Medical is developing a wireless, wearable disposable electrode patch to measure the electrical activity from the stomach, small intestine and colon. Anatomic issues are the focus of existing tests through endoscopies, colonoscopies and CT scans, but many if not most patients with abdominal pain, constipation, diarrhea or bloating.
In the Press
Yahoo Finance: 5 Ground-Breaking products from Healthcare Startups
Wall Street Journal: Where Most Investors Fear to Tread, Breakout Labs Funds Early-Stage Advanced Tech
Medical Device Daily: G-Tech Medical's wireless patch gives new meaning to the term gut check
It is commonly accepted that 15 to 20% of the US population have some form of gastrointestinal (GI) disorder. One need only visit a supermarket and see the amount of shelf space given to products that are gluten free, lactose free, soy-based or soy-free, have active culture probiotics or names like “Goodbelly” to understand that this is an issue that affects much of society.
IBS is the commonest and most frustrating diagnosing for my patients and me. Young women, and they are mostly young women, develop these complaints as teenagers and young adults. I follow the Rome algorithms to arrive at the diagnosis of IBS. I will have a detailed discussion with the patients explaining what is known about the pathophysiology of the disease.
The IBS in America survey was commissioned by the American Gastroenterological Association (AGA) and conducted with the financial support of Ironwood Pharmaceuticals, Inc. and Allergan plc. In total 3,254 IBS sufferers, both diagnosed and undiagnosed, were interviewed, as well as 302 physicians who treat IBS patients — 151 primary care physicians and 151 gastroenterologists.